Zosano Pharma Corporation (ZSAN)
(Delayed Data from NSDQ)
$3.64 USD
-0.05 (-1.36%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.64 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.64 USD
-0.05 (-1.36%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.64 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zosano Pharma Corporation (ZSAN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Zosano Pharma Corporation (ZSAN) closed at $1.70, marking a +0.59% move from the previous day.
Zosano (ZSAN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Zosano (ZSAN) is set to provide updates on the development path ahead for its lead candidate, M207, when it reports earnings results for first-quarter 2022.
Zosano Pharma Corporation (ZSAN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zosano Pharma Corporation (ZSAN) delivered earnings and revenue surprises of 0.00% and -10.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Zosano Pharma Corporation (ZSAN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zosano Pharma Corporation (ZSAN) delivered earnings and revenue surprises of 0.00% and -30.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zosano Pharma (ZSAN) in Focus: Stock Moves 6.3% Higher
by Zacks Equity Research
Zosano Pharma (ZSAN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Is a Disappointment in Store for Zosano (ZSAN) Q3 Earnings?
by Zacks Equity Research
Investors will be keen on updates on Qtrypta when Zosano (ZSAN) reports Q3 results.
New Strong Sell Stocks for September 3rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Friday's Top Movers: 3 Stocks to Watch
by Ryan McQueeney
Stocks opened higher on Friday morning amid continued trade tensions and major merger news. Here's a shortlist of today's top movers to keep an eye on as the trading week wraps up!
5 Drug Stocks That Could Be Big Winners this Earnings Season
by Arpita Dutt
Here is a look at five companies including Pfizer (PFE) that sport a favorable Zacks Rank and have a positive earnings ESP.